India, July 6 -- Vertex Pharmaceuticals Inc. (VRTX) announced it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for PrALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for cystic fibrosis in patients aged six years and older with at least one F508del mutation or another responsive CFTR mutation.
The LOI follows positive reimbursement recommendations from Canada's Drug Agency (CDA-AMC) in December 2025 and Institut national d'excellence en sante et services sociaux (INESSS) in April 2026.
Vertex noted that approximately 3,800 people across Canada are now eligible for ALYFTREK, with up to 60 individuals potentially gaining access to a therapy that treats the underlyin...